IPO Update: High-Flying Biopharma IPOs Average 77.1% Return Through Q2

 
• By Mandy Jackson

The performance of 29 biopharma firms that launched IPOs during the first half of 2020 is staggering compared with 28 drug developers that went public in the first half of 2019 with a 10% average return.

businessman hand holding dollar plane with IPO text ,business idea , business concept, analysis concept
High-flying IPO returns ranged from -33.1% for Ayala to +438.6% for Schrodinger • Source: Shutterstock

More from Financing

More from Business